Medscape

FDA OKs Subcutaneous Vedolizumab (Entyvio) for UC Maintenance Therapy

The US Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of vedolizumab (Entyvio SC, Takeda) for maintenance therapy in adults with moderately to severely active ...
Monthly Prescribing Reference

Entyvio for Subcutaneous Use Approved for Maintenance in Crohn Disease

Credit: Takeda. The approval was based on data from the phase 3 VISIBLE 2 trial. Results showed 48% of patients treated with vedolizumab SC were in clinical remission at week 52 compared with 34% of ...
Healio

Takeda’s Entyvio snags second FDA approval as ‘subcutaneous option’ for Crohn’s disease

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
Healio

FDA approves subcutaneous Entyvio as maintenance therapy for ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
FiercePharma

In 2nd attempt, Takeda scores FDA nod for subcutaneous version of Entyvio

In 2020, Europe endorsed a subcutaneous version of Takeda's Entyvio. More than three years later, the Japanese company has finally won over the FDA with its SC formulation. (Takeda) Nearly four years ...